Know Cancer

forgot password

A Randomized Double-Blind Parallel Group Study Comparing Casodex 50mg Plus Placebo to Casodex 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase

Phase 4
40 Years
90 Years
Open (Enrolling)
Neoplasms, Prostate, Prostate Cancer

Thank you

Trial Information

A Randomized Double-Blind Parallel Group Study Comparing Casodex 50mg Plus Placebo to Casodex 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase

Inclusion Criteria

Inclusion criteria:

- Men ≥40 and ≤85 years of age

- Must have asymptomatic prostate cancer that has progressed during androgen
deprivation therapy (rising PSA). PSA progression must have occurred after first-line
treatment with GnRH analogues ( e.g. leuprolide, goserelin) or orchiectomy. PSA
progression is defined by three rises in PSA each measured at least 4 weeks apart
within the previous year.

- Serum PSA ≥2 and ≤20ng/ml from central laboratory. One PSA retest from central
laboratory is allowed if the value is <2 or >20ng/ml; or if the PSA value is not
consistent with the previous rising PSA values that determined progression while on a
GnRH analogue.

- Serum Testosterone <50ng/ml from central laboratory.

- Non-metastatic prostate cancer as confirmed on prior bone scan performed within 8
weeks of screening.

- Expected survival ≥ 2 years

- ECOG Performance status 0, 1, or 2

Exclusion criteria:

- Additional hormonal therapy (excluding the current use of a GnRH analogue) within the
past 6 months of:

- Estrogens (e.g. megestrol, medroxyprogesterone, cyproterone, DES)

- Drugs with antiandrogenic properties (e.g., spironolactone if >50mg/day, flutamide,
bicalutamide*, ketoconazole**, progestational agents)

*The use of an antiandrogen during GnRH analogue induction for <6 weeks is
acceptable, but none within the 3 months prior to study entry.

**The use of topical ketoconazole is permitted prior to and during the study. NOTE:
Use of dietary and herbal supplements (e.g., selenium, Vitamin E, saw palmetto),
excluding daily vitamins, during the study is discouraged, but not prohibited. All
dietary and herbal supplement usage will be recorded in the eCRF.

- Treatment with oral glucocorticoids during the 3 months prior to randomization or
expectation of their use during the study.

- Prior chemotherapy for prostate cancer. (prior prostatectomy or radiotherapy to the
prostate are allowed)

- Prostate surgery including TUNA, TURP, TUIP, laser treatment, thermotherapy, balloon
dilatation, prosthesis, and cryosurgical ablation within 2 months prior to

- Current and/or previous use of the following medications:

- Finasteride (Proscar, Propecia), or Dutasteride (GI198745, AVODART) exposure within 6
months prior to study entry

- Anabolic steroids (within 6 months prior to study entry)

- Participation in any investigational or marketed drug trial within the 30 days prior
to the first dose of study drug or anytime during the study period.

- Any unstable serious co-existing medical condition(s) including but not limited to
myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
clinically evident congestive heart failure, or cerebrovascular accident within 6
months prior to Screening visit; uncontrolled diabetes; or peptic ulcer disease which
is uncontrolled by medical management.

- Abnormal liver function test greater than 1.5 times the upper limit of normal for
alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline
phosphatase [ALP] or bilirubin.

- Serum creatinine >2.0 times the upper limit of normal.

- History of another malignancy within five years that could affect the treatment of
prostate cancer or survival of the subject.

- History or current evidence of drug or alcohol abuse within the last 12 months.

- History of any illness (including psychiatric) that, in the opinion of the
investigator, might confound the results of the study or pose additional risk to the

- Known hypersensitivity to any 5 alpha-reductase inhibitor or to any drug chemically
related to dutasteride.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Time to disease progression with up to 18 months of treatment PSA progression monitored by monthly PSAs

Outcome Time Frame:

18 months, with 2 year safety extension phase

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

May 2007

Completion Date:

March 2013

Related Keywords:

  • Neoplasms, Prostate
  • Prostate Cancer
  • prostate cancer
  • androgen deprivation therapy
  • Neoplasms
  • Prostatic Neoplasms



GSK Investigational Site Bakersfield, California  93309
GSK Investigational Site Gainesville, Florida  32610
GSK Investigational Site Indianapolis, Indiana  46260
GSK Investigational Site New Orleans, Louisiana  70112
GSK Investigational Site Springfield, Massachusetts  01107
GSK Investigational Site Duluth, Minnesota  55805
GSK Investigational Site St. Louis, Missouri  63141
GSK Investigational Site Raleigh, North Carolina  27609
GSK Investigational Site Akron, Ohio  44304
GSK Investigational Site Fort Worth, Texas  76104
GSK Investigational Site Green Bay, Wisconsin  54301
GSK Investigational Site Park Ridge, Illinois  60068
GSK Investigational Site Baltimore, Maryland  21201
GSK Investigational Site Pittsburgh, Pennsylvania  15213
GSK Investigational Site Columbia, South Carolina  29210
GSK Investigational Site Germantown, Tennessee  38138
GSK Investigational Site Salem, Virginia  24153
GSK Investigational Site New York, New York  10021
GSK Investigational Site Birmingham, Alabama  35209
GSK Investigational Site Aurora, Colorado  80012
GSK Investigational Site Washington, District of Columbia  20307-5001
GSK Investigational Site Kansas City, Kansas  66160
GSK Investigational Site Henderson, Nevada  89014
GSK Investigational Site Seattle, Washington  98133